Personalis (NASDAQ:PSNL) CFO Sells $480,400.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00. Following the sale, the chief financial officer owned 198,833 shares in the company, valued at $2,387,984.33. This represents a 16.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42.

Personalis Stock Down 11.2%

Shares of PSNL stock traded down $1.35 during trading hours on Friday, reaching $10.75. 4,145,011 shares of the stock traded hands, compared to its average volume of 2,893,865. Personalis, Inc. has a 1-year low of $3.84 and a 1-year high of $12.53. The business has a fifty day moving average price of $7.23 and a 200 day moving average price of $8.21. The firm has a market capitalization of $1.13 billion, a PE ratio of -10.54 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Research analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Needham & Company LLC boosted their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. Morgan Stanley lowered their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, BTIG Research lowered their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Royal Bank of Canada grew its position in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its position in Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth bought a new stake in Personalis in the first quarter worth approximately $47,000. Finally, JPMorgan Chase & Co. grew its position in Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after acquiring an additional 24,621 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.